These additional findings included novel gene fusions and high-risk cytogenetic aberrations such as chromoanagenesis and IKZF1 loss, and the latter has a clinical implication in disease progression, prognosis prediction, and modification of therapy regimens in both myeloid and lymphoid neoplasm [43,44,45]. The gene discussed is IKZF1; the disease is lymphoid neoplasm.